Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egle

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Blood|August 16, 2014
Old and new news in CLL: "It's the pathway, stupid!"Alexander Egle
Blood|June 5, 2010
Riding the 2-edged swordAlexander Egle
Memo|April 4, 2017
Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of <i>memo</i>Alexander Egle
Future Oncology (London, England)|August 17, 2018
Plitidepsin: a potential new treatment for relapsed/refractory multiple myelomaMichael Leisch, Alexander Egle, Richard Greil
The FEBS Journal|January 7, 2015
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapyMaja Sochalska, Selma Tuzlak, Alexander Egle, et al.
The FEBS Journal|February 17, 2016
Bcl-2 proteins in development, health, and disease of the hematopoietic systemMatthias Kollek, Alexandra Müller, Alexander Egle, et al.
Leukemia & Lymphoma|December 5, 2012
Viral infections and their management in patients with chronic lymphocytic leukemiaThomas Melchardt, Lukas Weiss, Richard Greil, et al.
Memo|December 19, 2017
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017Teresa Magnes, Alexander Egle, Richard Greil, et al.
Nature Reviews. Clinical Oncology|June 3, 2009
Molecular and cellular mechanisms of CLL: novel therapeutic approachesLisa Pleyer, Alexander Egle, Tanja Nicole Hartmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2004
Bim is a suppressor of Myc-induced mouse B cell leukemiaAlexander Egle, Alan W Harris, Philippe Bouillet, et al.
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Blood|August 16, 2014
Old and new news in CLL: "It's the pathway, stupid!"Alexander Egle
Blood|June 5, 2010
Riding the 2-edged swordAlexander Egle
Memo|April 4, 2017
Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of <i>memo</i>Alexander Egle
Future Oncology (London, England)|August 17, 2018
Plitidepsin: a potential new treatment for relapsed/refractory multiple myelomaMichael Leisch, Alexander Egle, Richard Greil
The FEBS Journal|January 7, 2015
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapyMaja Sochalska, Selma Tuzlak, Alexander Egle, et al.
The FEBS Journal|February 17, 2016
Bcl-2 proteins in development, health, and disease of the hematopoietic systemMatthias Kollek, Alexandra Müller, Alexander Egle, et al.
Leukemia & Lymphoma|December 5, 2012
Viral infections and their management in patients with chronic lymphocytic leukemiaThomas Melchardt, Lukas Weiss, Richard Greil, et al.
Memo|December 19, 2017
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017Teresa Magnes, Alexander Egle, Richard Greil, et al.
Nature Reviews. Clinical Oncology|June 3, 2009
Molecular and cellular mechanisms of CLL: novel therapeutic approachesLisa Pleyer, Alexander Egle, Tanja Nicole Hartmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2004
Bim is a suppressor of Myc-induced mouse B cell leukemiaAlexander Egle, Alan W Harris, Philippe Bouillet, et al.
Pageof 13